CER Daily Newsfeed

ISPOR 2026: What the Plenary Sessions Signal for Drug Policy, Cancer Care, and Global Innovation

(4/21, Laura Dormer, The Evidence Base) comments “...Plenary 3: Innovation under pressure: How will US drug policy reshape innovation, evidence, and access globally?...The discussion will explore how constrained healthcare budgets, trade policy, and reference pricing are reshaping the global access environment. These forces have the potential to affect development decisions, pricing strategies, launch sequencing, and the types of evidence required to support regulatory and health technology assessment (HTA) submissions.” Full

Video: AAN 2026: Rituximab vs. Approved NMOSD Therapies, What the SPHERES Registry Reveals About Real-World Treatment Gaps

(4/20, Michael Levy, MD, PhD, Kennedy Ferruggia, Pharmacy Times) “...Pharmacy Times: What gaps in real-world practice does this registry and trial data expose, and where do you see NMOSD treatment heading next? Levy: I think the biggest gap is the question of the true relapse efficacy of rituximab, which has never been tested. One of the things that we're doing now is a study funded by PCORI to actually test rituximab against the new drugs. The trial is called NMO-BEST.” View Video

Video: Balancing Clinical Trial and Real-World Evidence in Multiple Myeloma

(4/21, Ajay K. Nooka, MD, MPH, FACP, Noopur S. Raje, MD, Surbhi Sidana, MD, OncLive) “In this segment, Dr. Ajay Nooka asks Dr. Surbhi Sidana to discuss how clinicians integrate evidence from randomized clinical trials with emerging real-world data when making treatment decisions in relapsed and refractory multiple myeloma. Dr. Sidana highlights that while clinical trials remain the foundation for establishing efficacy and safety, real-world evidence provides important insights into how therapies perform in broader patient populations, including those who may not meet strict trial eligibility criteria.” View Video